Drug Profile

AP 301

Alternative Names: AP-301 - Shanghai Alebund Pharmaceuticals; VS 505; VS-505 - Shanghai Alebund Pharmaceuticals

Latest Information Update: 03 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai Alebund Pharmaceuticals
Class Hyperphosphataemia therapies
Mechanism of Action Phosphate binding modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Hyperphosphataemia

Most Recent Events

26 Jun 2025 Shanghai Alebund Pharmaceuticals announces intention to submit NDA to NMPA for Hyperphosphatemia in third quarter of 2025
26 Jun 2025 Efficacy and adverse events data from a phase III trial in Hyperphosphataemia released by Alebund Pharmaceuticals
13 Jun 2025 Phase-III clinical trials in Hyperphosphataemia in USA (PO) (NCT06933472)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com